APA (7th ed.) Citation

Borkhardt, A., Qin, N., Keir, S. T., Bigner, D. D., Cole, A., Wölfl, M., . . . Mitra, S. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Borkhardt, Arndt, et al. Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-driven Medulloblastoma While Making Them Susceptible to Anti-CD47-induced Macrophage Phagocytosis via NF-kB-TGM2 Driven Tumor Inflammation. BMJ Publishing Group.

MLA (9th ed.) Citation

Borkhardt, Arndt, et al. Tacedinaline (CI-994), a Class I HDAC Inhibitor, Targets Intrinsic Tumor Growth and Leptomeningeal Dissemination in MYC-driven Medulloblastoma While Making Them Susceptible to Anti-CD47-induced Macrophage Phagocytosis via NF-kB-TGM2 Driven Tumor Inflammation. BMJ Publishing Group.